Floatz logo

Vinorelbine

Small Cell Carcinoma

EpicentRx, Inc.Phase 2Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Hycamtin
National Cancer Institute (NCI)
Phase 2BB
Lurbinectedin
SystImmune Inc.
Phase 3BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
EpicentRx, Inc.
Phase 2BB
Pembrolizumab
Thomas Jefferson University
Phase 2BB

View all 30 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Breast CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →